EVALUATION OF THE HER2/NEU EXPRESSION IN THE TISSUE OF METASTATIC AXILLARY LYMPH NODES IN BREAST CANCER PATIENTS USING THE [99mTs]TC-(HE)3-G3
- Authors: Bragina O.D.1,2, Tashireva L.A.1, Loos D.M.1,3, Vtorushin S.V.1,3, Shulga A.A.2,4, Konovalova E.N.2,4, Borodina M.E.5, Chernov V.I.1,2,6, Tolmachev V.M.7, Deyev S.M.2,4,6
-
Affiliations:
- Tomsk Cancer Research Institute
- National Research Tomsk Polytechnic University
- Siberian State Medical University
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
- Hertsen Moscow Oncology Research Institute
- National Research Center Kurchatov Institute
- Uppsala University
- Issue: Vol 16, No 2 (2024)
- Pages: 22-29
- Section: Research Articles
- Submitted: 08.06.2024
- Accepted: 26.06.2024
- Published: 21.08.2024
- URL: https://actanaturae.ru/2075-8251/article/view/27448
- DOI: https://doi.org/10.32607/actanaturae.27448
- ID: 27448
Cite item
Abstract
Anatomical visualization and molecular typing of tumor tissue of regional metastatic lymph nodes (mALN) in patients with breast cancer, it is an important clinical problem in modern oncology. According to the results of previous studies, the [99mTc]Tc-(HE)3-G3 has proven itself as a promising diagnostic agent that allows differentiating the status of the HER2/neu receptor of a primary breast tumor (p<0.05, Mann-Whitney test). In this regard, the purpose of this study is to explore the possibilities of using [99mTc]Tc-(HE)3-G3 to type the status of HER2/neu in patients with breast cancer. The study was conducted on clinical material including 20 patients with breast cancer (T2-4N1-3M0-1) before the systemic therapy (10 patients with overexpression of HER2/neu in metastases of axillary lymph nodes and 10 patients with negative) who underwent SPECT/CT scan 4 hours after injection of [99mTc]Tc-(HE)3-G3. Morphological and immunohistochemical studies of tumor tissue of metastatic axillary lymph nodes were performed in all patients with an assessment of HER2/neu status. Based on the results of our analysis, we found that the use of the mALN -to-contralateral and mALN-to-LDM ratios 4 hours after injection of [99mTc]Tc-(HE)3-G3 should be considered for typing the status of HER2/neu in mALN in breast cancer patients (p<0.05, Mann-Whitney test). At the same time, for the low/background parameter, the sensitivity and specificity indicators were 80% with a threshold value > 12.25.
About the authors
O. D. Bragina
Tomsk Cancer Research Institute; National Research Tomsk Polytechnic University
Author for correspondence.
Email: bragina_od@mail.ru
Russian Federation, Tomsk, 634009; Tomsk, 634050
L. A. Tashireva
Tomsk Cancer Research Institute
Email: bragina_od@mail.ru
Russian Federation, Tomsk, 634009
D. M. Loos
Tomsk Cancer Research Institute; Siberian State Medical University
Email: bragina_od@mail.ru
Russian Federation, Tomsk, 634009; Tomsk, 634050
S. V. Vtorushin
Tomsk Cancer Research Institute; Siberian State Medical University
Email: bragina_od@mail.ru
Russian Federation, Tomsk, 634009; Tomsk, 634050
A. A. Shulga
National Research Tomsk Polytechnic University; Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: bragina_od@mail.ru
Russian Federation, Tomsk, 634050; Moscow, 117997
E. N. Konovalova
National Research Tomsk Polytechnic University; Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: bragina_od@mail.ru
Russian Federation, Tomsk, 634050; Moscow, 117997
M. E. Borodina
Hertsen Moscow Oncology Research Institute
Email: bragina_od@mail.ru
Russian Federation, Moscow, 125284
V. I. Chernov
Tomsk Cancer Research Institute; National Research Tomsk Polytechnic University; National Research Center Kurchatov Institute
Email: bragina_od@mail.ru
Russian Federation, Tomsk, 634009; Tomsk, 634050; Moscow, 123098
V. M. Tolmachev
Uppsala University
Email: bragina_od@mail.ru
Sweden, Uppsala, 75185
S. M. Deyev
National Research Tomsk Polytechnic University; Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; National Research Center Kurchatov Institute
Email: bragina_od@mail.ru
Russian Federation, Tomsk, 634050; Moscow, 117997; Moscow, 123098
References
- Ge I., Erbes T., Juhasz-Böss I. // Gynecol Obstet Actions. 2022. V. 306. № 4. P. 943–957. doi: 10.1007/s00404-021-06352-9.
- Chen H., Zhou J., Chen Q., Deng Y. // Medicine (Baltimore). 2021. V. 100. № 26. P. e26531. doi: 10.1097/MD.0000000000026531.
- Sood R., Rositch A.F., Shakoor D., Ambinder E., Pool K., Pollak E., Mollura D., Mullen L., Harvey S. // Glob Oncol. 2019. V. 5. P. 1–17. doi: 10.1200/JGO.19.00127.
- Han L., Li L., Wang N., Xiong Y., Li Y., Gu Y. // Interferon Cytokine Res. 2018. V. 38. № 12. P. 578–582. doi: 10.1089/jir.2018.0085.
- Lower E.E., Khan S., Kennedy D., Baughman R.P. // Breast Cancer – Targets and Therapy. 2017. V. 9. P. 515–520. doi: 10.2147/BCTT.S137709.
- Gebauer M., Skerra A. // Annu. Rev. Pharmacol. Toxicol. 2020. V. 60. P. 391–415. doi: 10.1146/annurev-pharmtox-010818-021118.
- Tolmachev V., Orlova A., Sorensen J. // Semin. Cancer Biol. 2021. V. 72. P. 185–197. doi: 10.1016/j.semcancer.2020.10.005.
- Bragina O.D., Deyev S.M., Chernov V.I., Tolmachev V.M. // Acta Naturae. 2022. V. 14. № 2. P. 4–15. doi: 10.32607/actanaturae.11611.
- Pernas S., Tolaney S.M. // Ther. Adv. Med. Oncol. 2019. V. 11. P. 1758835919833519. doi: 10.1177/1758835919833519.
- Tolmachev V.M., Chernov V.I., Deyev S.M. // Russ. Chem. Rev. 2022. V. 91. RCR5034. https://doi.org/10.1070/RCR5034.
- Krasniqi A., D’Huyvetter M., Devoogdt N., Frejd F.Y., Sorensen J., Orlova A., Keyaerts M., Tolmachev V. // J. Nucl. Med. 2018. V. 59. P. 885–891. doi: 10.2967/jnumed.117.199901.
- Eissler N., Altena R., Alhuseinalkhudhur A., Bragina O., Feldwisch J., Wuerth Q., Loftenius A., Brun N., Axelsson R., Tolmachev V., et al. // Biomedicines. 2024. V. 12. № 5. P. 1088. doi: 10.3390/biomedicines12051088.
- Bragina O., von Witting E., Garousi J., Zeltchan R., Sandstrom M., Orlova A., Medvedeva A., Doroshenko A., Vorobyeva A., Lindbo S., et al. // J. Nucl. Med. 2021. V. 62. P. 493–499. doi: 10.2967/jnumed.120.248799.
- Bragina O., Chernov V., Larkina M., Rybina A., Zelchan R., Garbukov E., Oroujeni M., Loftenius A., Orlova A., Sörensen J., et al. // Theranostics. 2023. V. 13. P. 4858–4871. doi: 10.7150/thno.86770.
- Bragina O., Tashireva L., Loos D., Chernov V., Hober S., Tolmachev V. // Pharmaceutics. 2024. V. 16. № 4. P. 445. doi: 10.3390/pharmaceutics16040445.
- Shilova O.N., Deyev S.M. // Acta Naturae. 2019. V. 11. № 4. P. 42–53. doi: 10.32607/20758251-2019-11-4-42-53.
- Vorobyeva A., Schulga A., Konovalova E., Güler R., Löfblom J., Sandström M., Garousi J., Chernov V., Bragina O., Orlova A., et al. // Sci. Rep. 2019. V. 9. № 1. P. 9405. doi: 10.1038/s41598-019-45795-8.
- Bragina O., Chernov V., Schulga A., Konovalova E., Garbukov E., Vorobyeva A., Orlova A., Tashireva L., Sorensen J., Zelchan R., et. al. // J. Nucl. Medicine. 2022. V. 63. № 4. P. 528–535. doi: https://doi.org/10.2967/jnumed.121.262542.
- Wolff A.C., Hammond M.E.H., Allison K.H., Harvey B.E., Mangu P.B., Bartlett J.M., Bilous M., Ellis I.O., Fitzgibbons P., Hanna W., et al. // Pathol. Lab. Med. 2018. V. 42. P. 1364–1382. doi: 10.1200/JCO.2018.77.8738.
- Wolff A.C., Somerfield M.R., Dowsett M., Hammond M.E.H., Hayes D.F., McShane L.M., Saphner T.J., Spears P.A., Allison K.H. // J. Clin. Oncol. 2023. V. 41. P. 3867–3872. doi: 10.1200/JCO.22.02864.
- Bragina O.D., Chernov V.I., Garbukov E.Yu., Doroshenko A.V., Vorobyeva A.G., Orlova A.M., Tolmachev V.M. // Bull. Siberian Medicine. 2021. V. 20. № 1. P. 23–30. https://doi.org/10.20538/1682-0363-2021-1-23-30.
- Tolmachev V., Bodenko V., Oroujeni M., Deyev S., Konovalova E., Shulga A., Lindbo S., Hober S., Orlova A., Vorobyeva A. // Int. J. Mol. Sci. 2022. V. 23. № 23. P. 15181. doi: 10.3390/ijms232315181.
- Bragina O., Chernov V., Shulga A., Konovalova E., Hober S., Deyev S., Sorensen J., Tolmachev V. // Cancers. 2023. V. 15. P. 3149. doi: 10.3390/cancers15123149.
Supplementary files
![](/img/style/loading.gif)